{"analyses":[{"groupDescription":"Alpha-protected statistical analysis.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.0001","pValueComment":"Statistically significance was met if p-value \\< 0.05.","statisticalComment":"Two-sided type I error rate of 0.05.","statisticalMethod":"t-test, 2 sided"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"97.56","upperLimit":"99.39","value":"98.71"},{"groupId":"OG001","lowerLimit":"8.88","upperLimit":"16.25","value":"12.05"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"622"},{"groupId":"OG001","value":"308"}],"units":"Participants"}],"description":"Castration rate was defined as the cumulative probability of testosterone suppression to \\< 50 ng/dL. The rate was estimated for each treatment group using the Kaplan-Meier method and reported as percentage of participants.","dispersionType":"95% Confidence Interval","groups":[{"description":"Relugolix 120-mg tablet administered orally once daily for 48 weeks following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1.","id":"OG000","title":"Relugolix"},{"description":"Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan and Taiwan), every 3 months by subcutaneous injection.","id":"OG001","title":"Leuprolide Acetate"}],"paramType":"NUMBER","populationDescription":"All randomized participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Week 3 Day 1 (Day 15)","title":"Castration Rate At Week 3 Day 1","type":"SECONDARY","unitOfMeasure":"percentage of participants"}